ARGNF News and Press, Argen X NV From 02/24/23

Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. The Fund was down 7.1% (Institutional Shares) during the fourth quarter, compared to a gain of 2.2% for the Russell...

February 23 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webc...

January 27 , 202 3 Amsterdam , the Netherlands — argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (F...

Summary Argenx caught a strong bid in FY22 on the back of advancements in its Efgartigimod [Vyvgart] pipeline for Myasthenia Gravis. Demand began to fade rolling into the new year, with heavy outflows across the 3-months to-date. The company reported strong results in its Vyvgart se...

January 16 , 202 3 Amsterdam , the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareh...

Summary BAMCO’s 13F portfolio value decreased from $31.14B to $30.95B this quarter. Ron Baron decreased Rivian Automotive and Alphabet during the quarter. Their top five positions are at ~31% of the overall portfolio. This article is part of a series that provides an on...

Reported $ 40 2 million in preliminary * full-year 2022 global net VYVGART sales ADHERE topline results now expected in second quarter of 2023 ; Stage B enrollment has surpassed projected target of 130 patients Registra...

Summary Immunovant is developing a similar drug to argenx, but at 10% of argenx’s valuation, offering a good option value and a hedge against owning argenx. Immunovant has a new generation anti-FcRn IMVT-1402, and recent pre-clinical data showed that it does not impact albumin le...

Summary BMEZ’s portfolio has a combination of unknown small-cap "next generation" healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...